RT Journal Article
SR Electronic
T1 Enrichment of the Janus kinase (JAK) activation signature in severe asthma sputum: Correlation with IL-13 expression
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA4897
DO 10.1183/13993003.congress-2016.PA4897
VO 48
IS suppl 60
A1 Pavlidis, Stelios
A1 Adcock, Ian
A1 Chung, Fan
A1 Rowe, Anthony
A1 Rossios, Christos
A1 Pandis, Ioannis
A1 Djukanovich, Ratko
A1 Sterk, Peter
A1 Guo, Yike
A1 Wiegman, Coen
YR 2016
UL https://publications.ersnet.org//content/48/suppl_60/PA4897.abstract
AB Rationale: Activation of multiple cytokine receptors is reported to play an important role in asthma via the Janus kinases (JAK) pathway. IL-13 is known to activate JAKs. We investigated whether this pathway was activated in the sputum and blood of patients from the U-BIOPRED cohort.Methods: Sputum transcriptomics data from 120 subjects with severe asthma (SA) who were smokers (SAsm) or non-smokers (SAn), mild moderate asthmatics (MMA) or healthy controls (HC). Blood transcriptomic data from 312 subjects was also obtained. We used gene set variation analysis (GSVA) to study the KEGG JAK-STAT signalling pathway. IL-13 expression in sputum was detected by SomaScan.Results: The JAK-STAT signalling pathway was enriched in the sputum of asthmatic subjects compared to HC although this was only significant in the SAn group (p=0.01). Subgrouping asthmatics according to their sputum granulocyte status indicated that patients with neutrophilic and mixed granulocytic asthma had the highest JAK-STAT enrichment compared to HC, eosinophilic asthma and paucigranulocytic asthma (all FDR<10-6). There was no correlation between JAK-STAT enrichment and sputum IL-13 levels. JAK-STAT activation was seen in blood.Conclusions: High activation of JAK-STAT signalling in neutrophilic and mixed granulocytic asthma suggests that these subjects may be suitable for inhaled anti-JAK therapy.